Silence and AstraZeneca extend R&D alliance

Wednesday 14 July 2010

Silence Therapeutics Plc has announced a one-year extension of its three-year old research and development collaboration with AstraZeneca Plc aimed at identifying five siRNA molecules for respiratory and oncology indications.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom